Elutia Inc. Reports Strong Growth and Strategic Advances

Aziyo Biologics, Inc. Class A ( (ELUT) ) has released its Q2 earnings. Here is a breakdown of the information Aziyo Biologics, Inc. Class A presented to its investors.

Elutia Inc., a pioneer in drug-eluting biomatrix technologies, focuses on developing and commercializing products that enhance compatibility between medical devices and patients, primarily in the healthcare sector. The company is known for its innovative solutions aimed at improving patient outcomes.

In its latest earnings report, Elutia Inc. highlighted significant growth driven by the adoption of its EluPro™ product, which saw a 49% sequential increase in revenue for the second quarter of 2025. The company also announced advancements in its next-generation drug-eluting biomatrix pipeline, targeting the breast reconstruction market.

Key financial metrics revealed a 33% year-over-year increase in BioEnvelope product sales, totaling $3.5 million, with EluPro now accounting for two-thirds of these sales. Despite a net loss of $9.6 million, this was a marked improvement from the $28.2 million loss in the previous year. The company’s gross margin improved to 48.8% from 44.5%, and adjusted gross margin rose to 62.4% from 58.0%.

Strategically, Elutia has expanded its market presence with over 160 VAC-approved centers and a growing customer base, supported by a strategic partnership with Boston Scientific. The company also regained control of its cardiovascular portfolio, contributing $736K in revenue for the quarter.

Looking ahead, Elutia’s management remains optimistic, projecting BioEnvelope sales to approach a $20 million annualized run rate by year-end. The company is also focused on advancing its NXT-41 platform, with FDA clearance expected in the coming years, positioning it to capture a significant share of the $1.5 billion breast reconstruction market.